The remarkable impact of bivalent HPV vaccine in Scotland
Menée en Ecosse auprès de 138 692 femmes nées entre 1988 et 1996 et ayant réalisé un frottis de dépistage à 20 ans, cette étude analyse l'effet, sur la prévalence de néoplasie cervicale intraépithéliale de grade 3 ou supérieur, de 3 doses du vaccin bivalent contre le papillomavirus humain (HPV) administrées à l'âge de 12 -13 ans
It was initially believed that prophylactic human papillomavirus (HPV) vaccines were probably type specific and provided protection only against infection with, and disease due to, the types of HPV the vaccines were targeted against. Given the predominance of the two most oncogenic HPV types (16 and 18) across all HPV related cancers, the two first generation vaccines (a bivalent vaccine targeting types 16 and 18 and a quadrivalent vaccine targeting types 6, 11, 16, and 18) offered important potential for meaningful cancer prevention even with no cross protection.
BMJ 2019